A Phase 2A, Single Arm, Multicentre, Study of ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy.
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Varlitinib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors ASLAN Pharmaceuticals
- 18 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Sep 2015 New trial record
- 15 Sep 2015 According to Aslan media release, Clinical Trial Applications (CTA) was approved in Singapore and Taiwan to conduct this trial.